Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Larocca

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Haematologica|January 8, 2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trialAntonio Palumbo, Alessandra Larocca, Mariella Genuardi, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.
Leukemia & Lymphoma|May 26, 2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match studyMassimo Offidani, Pietro Leoni, Sara Bringhen, et al.
Blood Cancer Journal|July 19, 2024
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.
Blood|August 27, 2013
The impact of response on bone-directed therapy in patients with multiple myelomaAlessandra Larocca, J Anthony Child, Gordon Cook, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
American Journal of Hematology|December 23, 2016
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trialsMassimo Gentile, Valeria Magarotto, Massimo Offidani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2020
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation SequencingMattia D'Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, et al.
Cells|May 13, 2026
MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple MyelomaMaría Labrador, Sara Cozzubbo, Mariangela Porro, et al.
Haematologica|April 26, 2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapyMaría-Victoria Mateos, Sara Bringhen, Paul G Richardson, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Haematologica|January 8, 2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trialAntonio Palumbo, Alessandra Larocca, Mariella Genuardi, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.
Leukemia & Lymphoma|May 26, 2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match studyMassimo Offidani, Pietro Leoni, Sara Bringhen, et al.
Blood Cancer Journal|July 19, 2024
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.
Blood|August 27, 2013
The impact of response on bone-directed therapy in patients with multiple myelomaAlessandra Larocca, J Anthony Child, Gordon Cook, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
American Journal of Hematology|December 23, 2016
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trialsMassimo Gentile, Valeria Magarotto, Massimo Offidani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2020
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation SequencingMattia D'Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, et al.
Cells|May 13, 2026
MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple MyelomaMaría Labrador, Sara Cozzubbo, Mariangela Porro, et al.
Haematologica|April 26, 2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapyMaría-Victoria Mateos, Sara Bringhen, Paul G Richardson, et al.
Pageof 10